Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of Cinacalcet tablets, a medication used for treatment of high ...

The U.S. unit of Indian drugmaker Dr. Reddy’s Laboratories is recalling 331,590 bottles of cinacalcet tablets used to treat hyperparathyroidism due to the presence of a known carcinogen. | The U.S.

Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of Cinacalcet tablets in the US due to manufacturing issues. The ...

Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of Cinacalcet tablets in the US due to manufacturing issues. The ...

The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.

During the initial titration phase of up to 16 weeks, patients received increasing dosages of cinacalcet until the serum calcium concentration was <2.5 mmol/l, the highest possible dosage was ...

Cinacalcet is an effective treatment for secondary hyperparathyroidism in patients on dialysis. Until now, no randomized, placebo-controlled, long-term trial has tested this drug in individuals ...

Stocks to watch on Monday, November 4, 2024: Indian bourses are preparing for a negative start on Monday, indicated GIFT ...

Cinacalcet (Sensipar ® /Mimpara ®, Amgen Inc., Thousand Oaks, CA), the first-in-class calcimimetic agent approved for treatment of secondary hyperparathyroidism in dialysis patients, is ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

The recall is due to the 'presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit', it added.

Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of a medication used to treat high calcium levels in the blood and ...